Since 2014
Adefovir dipivoxil nella terapia dell’epatite B cronica: profilo farmacologico clinico ed economico
Farmeconomia
View Archive Info| Field | Value | |
| Title |
Adefovir dipivoxil nella terapia dell’epatite B cronica: profilo farmacologico clinico ed economico
|
|
| Creator |
Pradelli, Lorenzo
Eandi, Mario |
|
| Subject |
Pharmacoeconomics; Health economics
Chronic hepatitis B (CHB); Adefovir dipivoxil (ADV); Health care economics |
|
| Description |
Despite the fact that an effective vaccine against hepatitis B virus (HBV) has been available for over 30 years, the worldwide prevalence of this infection is still very high. Until recently, there were only two effective therapeutic options for chronic hepatitis B (CHB), interferon and lamivudine, but both are considered suboptimal therapies, for different reasons. Adefovir dipivoxil (ADV) is the oral prodrug of adefovir, an acyclic nucleotide analogue that demonstrated virological and clinical effectiveness against HBV in experimental and real world settings. In this paper the main pharmacological and clinical evidence of ADV in CHB is reviewed. Health care economics data on the direct costs of CHB in different countries are presented and potential economical consequences of its introduction in Italy are discussed.
|
|
| Publisher |
SEEd Medical Publishers
|
|
| Date |
2005-12-15
|
|
| Type |
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion — |
|
| Format |
application/pdf
|
|
| Identifier |
http://journals.edizioniseed.it/index.php/FE/article/view/849
10.7175/fe.v6i4.849 |
|
| Source |
Farmeconomia. Health economics and therapeutic pathways; Vol 6, No 4 (2005); 289-300
2240-256X 1721-6915 |
|
| Language |
eng
|
|
| Relation |
http://journals.edizioniseed.it/index.php/FE/article/view/849/933
|
|
| Rights |
Copyright (c) 2005 Farmeconomia. Health economics and therapeutic pathways
http://creativecommons.org/licenses/by-nc/4.0 |
|